DOYLESTOWN, Pa., June 14, 2017 -- Peter Marchesini, Chief Operating Officer of Alamo Pharma Services (“Alamo”), will participate in CBI’s sixth annual “Bio/Pharma Product Forecasting and Analytics Summit” taking place in Philadelphia on June 15 and 16, 2017. The focus of the summit is to help attendees improve forecasting to optimize revenue potential for pipeline and inline products. Marchesini, along with Noetyx President and Chief Executive Officer Lenny Vicciardo, will be leading a discussion on “Building an Organizational Infrastructure Based on Long-Term Forecasts.”
|
||||||||
With more than 20 years experience in the pharmaceutical industry, Marchesini specializes in helping companies define the smartest plans to effectively address opportunities as they arise to maximize the return on investment. Alamo offers pharmaceutical and biotech companies an innovative and thoughtful approach to deploying high impact sales teams, offering turnkey solutions for clients in service offerings that range from recruiting and hiring to training and ongoing operational support of sales teams. Marchesini’s expertise is further enhanced by his role on the faculty at Rutgers Business School, where he co-teaches the course Managing the Pharmaceutical Sales Force, a core course of the Pharmaceutical MBA program.
“I am looking forward to this session and what promises to be a thought provoking and informative discussion,” says Marchesini. “The foundation of the success of a commercial organization and to the expectations of its investors or management team is how well the forecast is generated and how the commercial execution compares to the forecast. Being able to share insights on this topic alongside an industry expert like Lenny is a privilege, and to lead the discussion at this particular summit is an honor.”
The Marchesini/Vicciardo session will help attendees consider how leading organizations strategically evaluate market events/industry trends and make operational decisions rooted in data and insights. In turn, these decisions allow professionals to be better equipped to:
- Build the best organizational structure
- Modify the sales team structure with an eye for opportunity
- Maximize profitability through valuation of second and third products
- Support team development
- Ensure cross-functional buy-in
After more than 30 years in the pharmaceutical industry, Vicciardo has developed an extensive background in management of strategy and analytics, market research, forecasting, strategic planning, and more. Prior to launching Noetyx, he was President of inVentiv Health Pharma Analytics Division, Health Products Research, and served in executive positions at other leading organizations. Vicciardo sees his teaming with Marchesini on this CBI Summit session as a win-win for attendees. “The industry is constantly evolving,” says Vicciardo. “It is critically important for companies to stay informed and in step with the latest developments. Pairing up with Pete on this discussion will provide an interesting and enlightening dialogue as we share our insights on the optimal way to forecast and the commercial thinking that needs to be considered to improve accuracy of those forecasts, and their impacts on the business of pharma.”
The CBI summit will take place at the Hyatt at the Bellevue Hotel in Philadelphia. The session featuring Marchesini and Vicciardo is scheduled for 11 a.m. on Friday, June 16.
About Alamo Pharma Services
Founded in 2011, Alamo Pharma Services offers pharmaceutical and biotech companies vital solutions to bring their products to market efficiently and successfully. Based out of its offices in Doylestown, Pa., Alamo offers companies vast commercialization experience, customized recruiting of sales teams, superior training, and committed support services. For more information regarding Alamo, visit AlamoPharmaServices.com or email [email protected].
Alamo is part of the Mission Family of Companies, a collection of wholly-owned subsidiaries created to diversify offerings and build forward-thinking partnerships with other pharmaceutical and biotech companies. Other Mission companies include BioComp Pharma, Inc., a generic drug marketer; ProSolus, Inc., a transdermal drug developer and manufacturer; Espada Dermatology, Inc., a prescription and esthetic dermatology company; as well as BexR Logistix, LLC and their subsidiary company, EPIC Fulfillment, Inc., the logistics and fulfillment arms of Mission. To learn more, please visit www.missionfamilyofcompanies.com.
# # #
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dd28fd22-202b-48eb-a9f1-4aee0eff892e
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/36c7697c-456a-4b9d-87a3-c32e1a2c240e
Drew Deeter Alamo Pharma Services 215.348.3890 [email protected]


TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



